Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA (NYSE:IQV) announced that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026 at 9:30 a.m. ET.
A live audio webcast will be available on the company investor relations website, with a replay posted later the same day.
IQVIA (NYSE:IQV) announced that chairman and CEO Ari Bousbib will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 9:20 a.m. ET. A live audio webcast will be available on the IQVIA Investor Relations website, with a replay available later that day.
IQVIA (NYSE: IQV) published its 2025 Sustainability Report, highlighting progress across People, Public and Planet pillars. Key metrics include >230,000 AI learning engagements, >2,000 leadership program participants, activation of Brazil and Argentina sites enrolling 5,700 patients toward a 47,000 global trial target, and 56 Prime Sites.
Environmental actions include 100% My Green Lab certification, test kits using ≥98% recycled materials and a 70% cut in cold‑chain packaging emissions.
IQVIA (NYSE: IQV) announced it will acquire certain discovery services assets from Charles River Laboratories, adding five sites that offer in vitro New Approach Methodologies (NAMs) and a small-molecule AI platform.
The assets include >20 years of curated scientific data, have supported 100+ molecules entering clinical trials and several approved drugs. The deal expands IQVIA Laboratories into an end-to-end drug discovery platform. The transaction is expected to close in the second quarter, 2026.
IQVIA (NYSE:IQV) said CFO Ron Bruehlman and SVP FP&A and incoming CFO Mike Fedock will speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026 at 11:00 a.m. ET.
A live audio webcast and same‑day replay will be available on IQVIA's Investor Relations website.
IQVIA (NYSE:IQV) and Duke Clinical Research Institute (DCRI) announced a strategic collaboration on February 10, 2026 to accelerate clinical research in obesity and related cardiometabolic conditions. The partnership combines IQVIA operational scale and real-world data with DCRI academic trial design and execution.
Key capabilities include access to patients across 56 countries and >3,000 sites, IQVIA’s experience with >120 obesity trials and >90,000 patients enrolled, and combined analytics, biostatistics and AI-enabled trial execution to support faster, more representative studies and regulatory submissions.
IQVIA (NYSE:IQV) reported fourth-quarter 2025 revenue of $4,364M and full-year revenue of $16,310M, with fourth-quarter GAAP net income of $514M and full-year GAAP net income of $1,360M. Adjusted diluted EPS was $3.42 Q4 and $11.92 full-year. R&DS backlog totaled $32.7B and quarterly R&DS bookings exceeded $2.7B (book-to-bill 1.18x). Operating cash flow was $735M Q4 and $2,654M full-year; free cash flow was $561M Q4 and $2,051M full-year. Full-year 2026 guidance: revenue $17,150–17,350M, Adjusted EBITDA $3,975–4,025M, Adjusted diluted EPS $12.55–12.85.
IQVIA (NYSE:IQV) announced a strategic, long-term collaboration with Boehringer Ingelheim to use IQVIA’s Data-as-a-Service (DaaS+) platform as the accelerator for global commercial data harmonization and transformation.
The deal targets harmonized market, brand and franchise reporting across 59 countries, cloud-native ingestion, global product mastering, and aims to support upcoming launches, improve market performance and enable AI-powered analytics.
IQVIA (NYSE:IQV) was named No. 1 in the Health Care: Pharmacy and Other Services category on the 2026 Fortune® World’s Most Admired Companies™ list.
This marks IQVIA's fifth consecutive year at No. 1 in its sector and its ninth consecutive year on the list. IQVIA ranked first in seven of nine evaluated attributes, including innovation, people management, use of corporate assets, financial soundness, long-term investment value, quality of products/services, and global competitiveness. Fortune and Korn Ferry analyzed 685 companies and surveyed more than 3,000 executives for the annual reputational ranking.
IQVIA (NYSE:IQV) will announce its fourth-quarter and full-year 2025 financial results before market open on Thursday, February 5, 2026. Management will host a conference call and live webcast at 9:00 a.m. Eastern Time the same day. The earnings release, financial information and presentation slides will be posted on the IQVIA Investor Relations site (http://ir.iqvia.com). Interested parties must register in advance to join the conference call; registrants receive a confirmation email with dial-in, unique passcode and registrant ID. A replay of the webcast will be available about two hours after the live event on the investor site.